Unlike the dual effect of m6A modification on cell proliferation, m6A commonly promote the chemoresistance of cancer cells, since up‐regulation of METTL3 and down‐regulation of FTO/ALKBH5 are frequently observed in drug resistance cancer cells, hinting that targeting m6A might be a feasible direction for drug resistant cancer therapy. This evidence concerns the gene METTL3 and cancer.